Clinical Treatment Score at 5 Years (CTS5) is an algorithm developed to identify patients with estrogen receptor–positive breast cancers at higher late distant recurrence (LDR) risk. We tested its clinical validity on a retrospective cohort of 603 real-life patients. CTS5 was shown to be prognostic on the risk of LDR for pre- and postmenopausal patients, supporting its use to better tailor the prescription of extended endocrine therapy.
Validation of CTS5 on a Retrospective Cohort of Real-Life Pre- and Postmenopausal Patients Diagnosed With Estrogen Receptor–Positive Breast Cancers: Is It Prognostic?
Villasco A.
First
;Agnelli F.;D'Alonzo M.;Accomasso F.;Sismondi P.;Biglia N.Last
2021-01-01
Abstract
Clinical Treatment Score at 5 Years (CTS5) is an algorithm developed to identify patients with estrogen receptor–positive breast cancers at higher late distant recurrence (LDR) risk. We tested its clinical validity on a retrospective cohort of 603 real-life patients. CTS5 was shown to be prognostic on the risk of LDR for pre- and postmenopausal patients, supporting its use to better tailor the prescription of extended endocrine therapy.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S152682092030152X-main.pdf
Accesso riservato
Tipo di file:
PDF EDITORIALE
Dimensione
1.86 MB
Formato
Adobe PDF
|
1.86 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
